NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
Clinical Trials
77 trialsNCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT00807027 2025-10-10
Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
GC Cell Corporation
Phase 3 Completed
NCT03679754 2025-08-28
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
Alaunos Therapeutics
Phase 1 Completed
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT03330197 2025-08-12
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Alaunos Therapeutics
Phase 1/2 Terminated
NCT03636477 2025-08-12
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
Alaunos Therapeutics
Phase 1 Completed
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT04479241 2025-06-05
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology, Inc.
Phase 2 Completed
NCT04704154 2025-04-18
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
Phase 2 Completed
NCT02026271 2025-04-16
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Alaunos Therapeutics
Phase 1 Completed
NCT03632135 2025-04-15
CSCRGBM
Cordgenics, LLC
Phase 3 Completed
NCT03522298 2025-03-24
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Kazia Therapeutics Limited
Phase 2 Completed
NCT03150862 2025-02-04
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
BeiGene
Phase 1/2 Completed
NCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT06469138 2025-01-29
8479217
BerGenBio ASA
Phase 1 Completed
NCT02525692 2024-12-24
Oral ONC201 in Adult Recurrent Glioblastoma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT02490800 2024-06-26
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
Basilea Pharmaceutica
Phase 1/2 Completed
NCT03250299 2024-06-24
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Basilea Pharmaceutica
Phase 1 Terminated
NCT02014844 2024-05-29
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
ImmunityBio, Inc.
Phase 2 Completed
NCT02067156 2024-05-21
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
GenSpera, Inc.
Phase 2 Completed
NCT03043391 2024-04-08
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
Phase 1 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT02684058 2023-12-13
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Phase 2 Completed
NCT03684811 2023-11-18
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Novo Nordisk A/S
Phase 1/2 Completed
NCT02315534 2023-11-15
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed
NCT01081223 2023-06-01
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
Phase 1/2 Completed
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT01607905 2023-01-26
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT01177397 2022-12-13
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
Phase 1/2 Completed
NCT02858895 2022-10-24
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Medicenna Therapeutics, Inc.
Phase 2 Completed
NCT00479765 2022-06-22
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGelâ„¢ in Subjects With Recurrent Glioma
Boston Scientific Corporation
Phase 1/2 Terminated
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT02844439 2021-09-22
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Kadmon Corporation, LLC
Phase 2 Completed
NCT03034135 2021-09-13
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
Cantex Pharmaceuticals
Phase 2 Completed
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT02765165 2021-07-23
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Proximagen, LLC
Phase 1/2 Terminated
NCT03393000 2021-07-22
INTACT
Diffusion Pharmaceuticals Inc
Phase 3 Terminated
NCT02340156 2021-03-03
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
SynerGene Therapeutics, Inc.
Phase 2 Terminated
NCT02296476 2021-01-26
MK-8628-002
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT00586508 2020-09-24
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
Eli Lilly and Company
Phase 2 Completed
NCT02038218 2020-09-16
DM-CHOC-PEN
DEKK-TEC, Inc.
Phase 2 Completed